One of the most repeated selling points for SARMs is that, unlike steroids, they do not shut you down and therefore need no post-cycle therapy (PCT). It is a tidy story. It is also wrong for the muscle-building compounds, at least at the doses people actually use. This guide separates the marketing from the measured hormone data and explains where PCT is and is not relevant.
Why suppression happens at all
Your testosterone production is governed by a feedback loop: the brain releases signalling hormones (LH and FSH) that tell the testes to make testosterone, and when the body senses enough androgen activity, it turns those signals down. Anything that activates the androgen receptor strongly enough looks like testosterone to that loop. Because the muscle-targeting SARMs are androgen receptor agonists, the body reads them as an androgen and dials back its own production. This is not a side effect that some SARMs happen to have; it is a direct consequence of how they work.
What the trials measured
The clearest human evidence is the phase 1 study of ligandrol (LGD-4033) in healthy young men. Over just 21 days at modest doses, total testosterone, free testosterone, and sex-hormone-binding globulin all fell in a dose-dependent way, and follicle-stimulating hormone was suppressed too. Levels trended back toward baseline after the drug stopped, but the study confirms the core point: a muscle-selective SARM shuts down the gonadal axis in real people, quickly.
Ostarine (enobosarm) trials at the low doses used for muscle wasting (1 to 3 mg per day) show milder effects on the hormone axis than ligandrol, but suppression of free testosterone has still been reported. Recreational users take much higher doses than any trial tested, which pushes suppression further than the published data describes. Testolone (RAD140) has essentially no controlled hormone data in healthy people, but as a potent androgen receptor agonist it is expected to be strongly suppressive, and user-reported bloodwork is consistent with that.
The practical takeaway: the more potent and the higher the dose, the more suppression, and RAD140 and higher-dose ligandrol sit at the suppressive end. Suppression is real for these compounds. The suppression-free claim does not survive contact with the bloodwork.
The compounds that genuinely are not suppressive
Not everything sold in the SARM aisle acts on the androgen receptor. Two popular ones do not, and it is a category error to lump them in:
- Cardarine (GW501516) is a PPAR-delta agonist, an endurance and metabolism drug, not an androgen. It does not suppress testosterone and there is no PCT rationale for it. Its concern is different: animal studies showed it caused cancer at multiple sites, which is why its development was halted.
- Stenabolic (SR9009) is a REV-ERB agonist affecting circadian and metabolic pathways. It is also not an androgen and does not require PCT. Its oral bioavailability in humans is questionable, so whether it does much at all when swallowed is an open question.
Lumping these in with the muscle SARMs is where a lot of the confused advice comes from. They are metabolic drugs with their own separate risk stories.
What PCT actually is
PCT for suppression means using selective estrogen receptor modulators, most commonly tamoxifen or clomifene, to nudge the brain into releasing more LH and FSH and restart natural testosterone production. These are the same tools used after a steroid cycle. Some people recover on their own once a suppressive SARM is stopped, especially after short, low-dose exposure; others do not bounce back cleanly, particularly after longer or stacked use, or after RAD140.
Honest caveats: whether a given person needs a SERM, at what dose, and for how long is not well established from controlled trials in SARM users, because those trials do not exist. The recovery data is largely anecdotal bloodwork shared by users. SERMs themselves have side effects and are prescription medicines. So this is a description of how the axis and its recovery tools work, not a protocol recommendation.
A sensible way to think about it
- If you took an androgen-receptor SARM (ostarine, ligandrol, testolone), assume you were suppressed to some degree and that the honest answer is 'measure it'. Bloodwork before, during, and after is the only way to know your own response.
- The more potent the compound and the higher and longer the dose, the more likely a slow or incomplete recovery, and the more relevant recovery support becomes.
- If you took a non-androgen (cardarine, stenabolic), there is no suppression to recover from and no PCT rationale, worry about their other risks instead.
- SERMs like tamoxifen and clomifene are the standard recovery tools, but they are drugs in their own right, not supplements.
Bottom line
The blanket claim that SARMs never need PCT is false. The muscle-targeting, androgen-receptor SARMs are demonstrably suppressive in humans, more so at recreational doses, so recovery support is often relevant for them. The non-androgen compounds sold alongside them are not suppressive and have no PCT rationale, though they carry their own risks. Because the recovery data in real users is thin and unstandardised, individual bloodwork beats any generic rule. This is reference information, not medical advice.